AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the use of AI.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA's comments, has now been presented to Fortrea, the company's contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova's goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy.
"We are committed to meeting the highest regulatory standards, and we're confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process."
The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful.
Meanwhile, Vision AI has gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners.
Avant and Ainnova's FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically.
Avant maintains global licensing rights to Ainnova's platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova's technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential.
Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers.
Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform.
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Renovaro Inc. (NASDAQ: RENB) secured multiple U.S. patents for its federated AI learning technologies in biomedical research.
"Expanding our IP footprint in federated learning and AI-based data harmonization directly supports our long-term vision: to be the platform of choice for next-generation biomedical research and precision medicine," said David Weinstein, CEO, Renovaro.
These patents support secure, privacy-preserving data integration across hospitals and labs for applications in drug discovery and precision medicine. The move strengthens Renovaro's position in the $20 billion biomedical AI space.
Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI-powered EHR services. Its Readeable.AI platform converts unstructured medical documents into usable data for clinicians.
"These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision," said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle." We're driving digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider."
The company is focused on making EHR systems smarter, more efficient, and better suited to community health networks.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) launched its Definium Pace Select ET, an AI-powered digital X-ray system for high-volume medical settings.
"This launch reinforces our commitment to provide accessible, efficient, and high-quality care for patients, while alleviating stress from the technologist's workday by minimizing repetitive tasks and automating steps," said Jyoti Gupta, PhD, President and CEO of Women's Health and X-ray at GE HealthCare. "We remain dedicated to advancing our technology through transformative digital and AI-enabled capabilities that will remove barriers to timely and effective diagnostic imaging for any patient in need of X-ray imaging."
The system automates repetitive tasks and improves image consistency to help radiologists work more efficiently. It's designed to relieve staffing pressures while maintaining high imaging standards in busy hospitals.
Spectral AI, Inc. (NASDAQ: MDAI) submitted its DeepView System to the FDA for marketing approval under the De Novo pathway.
"This FDA submission is a major milestone for Spectral AI and the DeepView System, representing a crucial step toward bringing this innovative diagnostic device to market in the United States," said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI. "It provides clinicians with an immediate, data-driven assessment tool designed to assist clinical decision-making and may significantly improve patient outcomes."
The device uses multispectral imaging and AI to predict how burn wounds will heal, helping doctors make faster and more accurate treatment decisions. It's positioned as a first-of-its-kind diagnostic tool in burn care.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
Hundreds cheer Arizona Sen. Ruben Gallego as Democrats take offensive against Trump's tax bill
DAVENPORT, Iowa (AP) — Hundreds of people cheered Sen. Ruben Gallego at a town hall meeting in eastern Iowa Saturday as the first-term Arizona Democrat assailed the massive, Republican-backed tax bill signed by President Donald Trump as likely to make 'America poorer and sicker.' Gallego's upbeat event struck the opposite tone from Rep. Mike Flood's town hall meeting earlier in the week, when an even bigger crowd jeered the Nebraska Republican for most of a 90-minute event in his state to promote the bill. Democrats, searching for months after last year's election defeat for footing in opposing the aggressive tone struck by Trump in his second term in the White House, have gone on the offensive this month, still united in their frustration with Trump but suddenly energized in full-throated opposition to his signature legislation. 'I think this bill is helping Democrats see clearly what's at stake with the future of protections for so many regular Americans,' said Pete Wernimont of Waterloo, who drove 140 miles (225 kilometers) to see Gallego. 'I just hope they are there when it really matters a year from now.' While some Republicans in safe Republican districts are braving crowds to sell Trump's law, most in Congress are heeding GOP leaders' suggestion to keep lower public profiles, especially noteworthy during the August recess following closely on Trump's signing of the tax cut and spending reduction bill last month. Democratic activists are rallying to point out what they see as the measure's political liabilities for Republicans trying to hold their narrow majorities in Congress in next year's midterm elections. 'This is the galvanizing moment that's happening because Democrats now understand, we're the people that fight for the middle class and the working class of America,' Gallego told reporters before the event Saturday. 'This is a clarifying moment for us.' For two hours, the audience of some 300 people applauded and at times stood cheering for the Arizona Democrat, one of several party figures who have been attacking the bill in congressional districts represented by Republicans. He was in Rep. Mariannette Miller-Meeks' 1st Congressional District, among the most competitive in the nation in the past three congressional elections. For a party frustrated with an array of Trump administration initiatives, the measure has had its own energizing effect. 'I came here because I work in health care and this bill will hurt health care,' said Alexandra Salter, a physicians assistant from Davenport. 'I think we are getting more vocal about it, because we need to speak up.' The meeting contrasted sharply with Flood's meeting in Lincoln, Nebraska, on Monday, when an even larger crowd of 700 voiced vigorous opposition to the bill, locking in especially on its changes to Medicaid, the federally funded health care program for low-income American. The bill, which passed with no Democratic votes in the House or Senate, makes substantial cuts to the health care program, notably by imposing work requirements for many of those receiving aid. The same frustration that drew Wernimont to Davenport Saturday convinced Ann Ashburn of Aurora, Nebraska, to drive the 70 miles (113 kilometers) to Lincoln to face Flood on Monday. Ashburn learned about Flood's appearance through an Omaha-area Democratic group called Blue Dot and reached out to friends who joined her. She dismissed any suggestion that such opposition had been orchestrated. 'I think the momentum could have been much greater had we been better organized,' the 72-year-old retired executive said. For now, Republicans have their work cut out for them if they hope to use the measure as a reason for voters to return them to the majority in the 2026 elections. About two-thirds of U.S. adults expect the new law will help the rich, according to the poll from The Associated Press-NORC Center for Public Affairs Research. Most — about 6 in 10 — also think it will do more to hurt than help low-income people, according to the survey taken last. Gallego used his trip to Iowa, which included a requisite stop at the Iowa State Fair, to burnish his own profile in a state that, until 2020, traditionally had hosted the first event in the Democrats' presidential nominating process. Iowa Democrats hope to return to the front of the parade when the 2028 primaries and caucuses begin. Other figures already popular nationally with Democrats such as New York Rep. Alexandria Ocasio-Cortez have been making stops in Republican districts decrying the legislation. Ocasio-Cortez last month headlined an event in New York's 21st District, represented by Republican Elise Stefanik, noting among other items its Medicaid provisions. Vermont Sen. Bernie Sanders is scheduled to hold rallies Sunday in Republican-held House districts in North Carolina. He too planned to focus on Medicaid cuts, and note their impact on rural hospitals in the state where former Gov. Roy Cooper, a Democrat now running for U.S. Senate, worked with the GOP-controlled legislature to expand Medicaid coverage in 2023.
Canada News.Net
10 hours ago
- Canada News.Net
Crypto, private equity eyed for 401(k)s under new Trump directive
NEW YORK CITY, New York: Millions of Americans saving for retirement could one day see private equity and cryptocurrency added to their 401(k) investment options under an executive order signed by President Donald Trump, potentially giving these industries long-coveted access to trillions of dollars in retirement funds. The order directs the Labor Department and other agencies to redefine what qualifies as an approved asset under the Employee Retirement Income Security Act of 1974 (ERISA), which governs U.S. retirement plans. Currently, most 401(k) accounts are invested in stocks, bonds, cash, and a small share of heavily traded commodities like gold. Employers are legally required to act in the best interests of their employees when offering investment options. There will be no immediate changes. Federal agencies must first draft and finalize new regulations, likely a process of months or longer, before employers can expand available choices. Once implemented, retirement plans could include alternative assets such as private equity, cryptocurrencies, and real estate. The move is a win for the US$5 trillion private equity sector, which has long sought access to 401(k) accounts, and for cryptocurrency firms, many of which supported Trump's 2024 campaign and are seeking mainstream acceptance. Bitcoin rose two percent this week to $116,542, nearly doubling since Trump was elected. Under former President Joe Biden, regulators approached crypto investments in retirement accounts "with extreme care" due to volatility. Cryptocurrencies such as Bitcoin and Ethereum can swing 10 percent in a single day, compared with two percent to three percent for major stock indexes. "It was inevitable that bitcoin would make its way into American 401(k)s," said Cory Klippsten, CEO of Swan Bitcoin. "As fiduciaries realize bitcoin's risk-adjusted upside over the long term, we'll see growing allocations, especially from younger, tech-savvy workers." For private equity firms, 401(k) access would unlock a vast pool of new capital. Blackstone CEO Steve Schwarzman has described this as a "dream" for the industry since at least 2017. Private equity has historically returned about 13 percent annually since 1990, versus 10.6 percent for the S&P 500, but investments are illiquid, often tied up for years until underlying companies are sold. Bryan Corbett, president and CEO of the Managed Funds Association, said the industry looks forward to creating "a thoughtful framework" with the Trump administration to expand retirement options "with appropriate investor guardrails." Even after new rules are finalized, it could take years before private equity and crypto appear widely in retirement plans. Major firms like Fidelity, Vanguard, and T. Rowe Price would need to design compliant products, and employers may be slow to change plan menus. Vanguard said it has not committed to offering private assets in defined contribution plans but will continue to educate investors "to ensure a clear understanding of the opportunities and risks."
Toronto Sun
11 hours ago
- Toronto Sun
GUNTER: Canada still hasn't seen Carney's promised leadership
Canadian Prime Minister Mark Carney speaks during a press conference after a Cabinet meeting to discuss both trade negotiations with the US and the situation in the Middle East, at the National Press Theatre in Ottawa, Ontario, Canada on July 30, 2025. Photo by DAVE CHAN / AFP via Getty Images The chances of Canada convincing Donald Trump's White House to reverse his tariffs on a wide range of Canadian goods seems remote. There's a possibility cases working their way through the U.S. courts will — maybe within the next six to 12 months — find Trump has overstepped his authority to impose tariffs and reverse them. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Who knows, the U.S. Senate may even find its spine and take back much of its Constitutional authority over tariffs. It's also just possible large sections of his MAGA base will turn on Trump as his tariff policies increase inflation and unemployment. Could happen. In the meantime, Canada has to make whatever deal it can with Trump while also making itself more resilient against U.S. trade sanctions. Keep in mind that the Americans' much-touted deals with the E.U., the U.K. and Japan aren't really deals at all. There are no documents, the details are sketchy and the two sides in each now disagree over just what each deal contains. Trump just likes the show of being Mr. Tough Guy, of having other countries' leaders appear to bow before him and kiss his ring. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. It won't be easy for Canada to get the same kind of 'deal' as those other countries. Trump seems to have a special hate on for Canada. And we are being backburnered by the Trump administration. Our concerns are being handled by mid-level officials, not boss-to-boss, despite Prime Minister Mark 'Elbows Up' Carney insistence that he knows Trump, knows who to deal with him and is uniquely qualified to reach an agreement. If we could even just return to Harper-era export levels with the U.S., Canada would be far less vulnerable. Under Stephen Harper's government, about 75 per cent of our foreign trade was with our southern neighbour. Now, thanks to the Liberals' complete indifference to all things economic, Ottawa has taken the easy path for the last 10 years until we are reliant on the Americans for 90 per cent of our trade. This advertisement has not loaded yet, but your article continues below. They account for around one-quarter of our GDP, while we account for less than three per cent of theirs. That means Canada has a need for a deal, but lacks leverage. So we need to export more to other countries to make us less susceptible to shocks from the U.S. Read More But given all that, where is the leadership from Carney? Remember his expansive promises to bring down internal trade barriers and get major projects going that would help us expand our exports around the globe? Name me one such objective he has checked off to date. We're never going to get over our dependence on the U.S., nor should we want to. Theirs is the largest, richest economy in the world and we have primo access to it. This advertisement has not loaded yet, but your article continues below. But we do need to make the most of our natural resource potential by opening mines, building pipelines and constructing or expanding ports. Yet while Carney talks about all those things, his latest 'action' on constructing a promised economic corridor came Thursday when he promised Indigenous groups that would have a quasi veto over projects they disliked. To understand what's at stake, consider that new figures on the Trans Mountain pipeline, completed just last year, shows it will generate in short order about $13 billion in new income for oil companies and governments. Imagine if we had two or even three more pipelines for oil and liquefied natural gas (LNG), plus some major mines for the rare earth minerals currently in such demand. Yet if Canada has no trade deal with the U.S. (not even a faux one) and years and years more of lengthy negotiations on resource megaprojects, our economy will continue to sputter along. Columnists Toronto & GTA Toronto Blue Jays World Toronto & GTA
